Schrodinger, Inc. Stock Price, News & Analysis

Summary not available.

Summary not available.

Summary not available.

Summary not available.

Schrödinger (Nasdaq: SDGR) is set to release its first quarter 2023 financial results on May 4, 2023, after market close. A conference call will follow at 4:30 p.m. ET. Investors can access the live webcast on the company's website and by phone using conference ID 21402709. Schrödinger employs a physics-based computational platform to expedite the discovery of new therapeutics and materials, significantly reducing time and costs compared to traditional methods. Founded in 1990, the company has around 800 employees and collaborates with clients across more than 70 countries. To explore further, visit www.schrodinger.com.

Schrödinger, Inc. (Nasdaq: SDGR) announced the granting of stock options and restricted stock units (RSUs) to new employees as part of its 2021 Inducement Equity Incentive Plan. On April 14, 2023, the company issued a non-statutory stock option for 2,400 shares with an exercise price of $27.49, equal to the closing stock price on that date. Additionally, 1,800 RSUs were granted. Both grants are intended to facilitate employee retention and motivation, with vesting schedules over four years. Schrödinger utilizes a physics-based computational platform to expedite drug and material discovery, serving global biopharmaceutical, industrial, and academic sectors. Founded in 1990, it employs approximately 800 individuals and collaborates with organizations in over 70 countries.

Schrödinger, Inc. (Nasdaq: SDGR) announced the granting of stock options to 10 newly hired employees on March 19, 2023. A total of 32,700 shares were offered as an inducement for employment, under the 2021 Inducement Equity Incentive Plan. The stock options have an exercise price of $25.62 per share, matching the stock's closing price on March 17, 2023. The options have a ten-year term and will vest over four years, with different vesting schedules for U.S. and international employees. This initiative reflects Schrödinger's commitment to attract talent in the competitive biopharmaceutical sector.

Schrödinger, Inc. (Nasdaq: SDGR) reported a 31% increase in total revenue for 2022, reaching $181.0 million. In Q4 2022, total revenue rose by 23% to $56.8 million, driven by a 24% increase in software revenue, totaling $47.8 million. Drug discovery revenue nearly doubled year-over-year to $45.4 million. The company expects continued growth in 2023, projecting software revenue growth of 13-17% and drug discovery revenue of $70-90 million. Operating expenses for 2022 stood at $247.8 million, with a net loss of $149.2 million. Despite challenges, Schrödinger is advancing its drug pipeline and improving financial metrics.

Schrödinger, Inc. (Nasdaq: SDGR) announced on February 15, 2023 the grant of stock options for 45,600 shares to 11 new employees, including international hires. This inducement is part of the company’s 2021 Inducement Equity Incentive Plan and follows Nasdaq Listing Rule 5635(c)(4). Each option is priced at $24.39, the closing stock price on the grant date. Options vest over four years, with 25% vesting after one year and the remainder based on service duration. Schrödinger leverages its physics-based computational platform for drug discovery and materials applications, supporting a global clientele while employing over 800 people worldwide.